Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivan Babic

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Scientific Reports|May 21, 2020
IRE1α and IGF signaling predict resistance to an endoplasmic reticulum stress-inducing drug in glioblastoma cellsJeffrey J Rodvold, Su Xian, Julia Nussbacher, et al.
Oncotarget|October 31, 2015
Multiple spatially related pharmacophores define small molecule inhibitors of OLIG2 in glioblastomaIgor F Tsigelny, Rajesh Mukthavaram, Valentina L Kouznetsova, et al.
Scientific Reports|November 1, 2025
Pan-cancer Myc modulator that targets Myc-α-tubulin interaction to drive selective mitotic catastropheJessica Teitel, Margaret Farah, Michele L Dziubinski, et al.
Cell Metabolism|October 22, 2013
mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-MycKenta Masui, Kazuhiro Tanaka, David Akhavan, et al.
Journal of Neuro-Oncology|May 4, 2013
Lyophilized brain tumor specimens can be used for histologic, nucleic acid, and protein analyses after 1 year of room temperature storageSergey Mareninov, Jason De Jesus, Desiree E Sanchez, et al.
Cell Metabolism|May 28, 2013
EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancerIvan Babic, Erik S Anderson, Kazuhiro Tanaka, et al.
Cancer Discovery|March 28, 2013
De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patientsDavid Akhavan, Alexandra L Pourzia, Alex A Nourian, et al.
Cancer Discovery|December 7, 2011
Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistanceKazuhiro Tanaka, Ivan Babic, David Nathanson, et al.
Biorxiv : the Preprint Server for Biology|February 23, 2026
ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinomaDhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2013
The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomasBeatrice Gini, Ciro Zanca, Deliang Guo, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Scientific Reports|May 21, 2020
IRE1α and IGF signaling predict resistance to an endoplasmic reticulum stress-inducing drug in glioblastoma cellsJeffrey J Rodvold, Su Xian, Julia Nussbacher, et al.
Oncotarget|October 31, 2015
Multiple spatially related pharmacophores define small molecule inhibitors of OLIG2 in glioblastomaIgor F Tsigelny, Rajesh Mukthavaram, Valentina L Kouznetsova, et al.
Scientific Reports|November 1, 2025
Pan-cancer Myc modulator that targets Myc-α-tubulin interaction to drive selective mitotic catastropheJessica Teitel, Margaret Farah, Michele L Dziubinski, et al.
Cell Metabolism|October 22, 2013
mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-MycKenta Masui, Kazuhiro Tanaka, David Akhavan, et al.
Journal of Neuro-Oncology|May 4, 2013
Lyophilized brain tumor specimens can be used for histologic, nucleic acid, and protein analyses after 1 year of room temperature storageSergey Mareninov, Jason De Jesus, Desiree E Sanchez, et al.
Cell Metabolism|May 28, 2013
EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancerIvan Babic, Erik S Anderson, Kazuhiro Tanaka, et al.
Cancer Discovery|March 28, 2013
De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patientsDavid Akhavan, Alexandra L Pourzia, Alex A Nourian, et al.
Cancer Discovery|December 7, 2011
Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistanceKazuhiro Tanaka, Ivan Babic, David Nathanson, et al.
Biorxiv : the Preprint Server for Biology|February 23, 2026
ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinomaDhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2013
The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomasBeatrice Gini, Ciro Zanca, Deliang Guo, et al.
Pageof 4